Celcuity Inc. (CELC) stock fell 22.41 percent to $95.41, losing $27.55 on Tuesday, despite announcing detailed positive efficacy data from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib.
The stock is currently trading at $95.41, compared to its previous close of $122.96 on the Nasdaq. During the session, it reached a high of $99.83 and a low of $94.32, with trading volume climbing to 1,383,663 shares, notably higher than its average daily volume of 938,892.
The sell-off occurred as the clinical-stage biotechnology company prepared to present late-breaking data on its breast cancer treatment candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting. Though the study demonstrated that the gedatolisib-triplet nearly doubled median progression-free survival (PFS) to 11.1 months compared to 5.6 months for the control arm.
Celcuity Inc.'s 52-week range is $11.09 to $151.02.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.